Key Highlights: Implications: Anupam Rasayan’s acquisition of a 48.2% controlling stake in Bliss GVS Pharma at ₹299/share completes its forward integration into finished‑dose formulations,...
Key Highlights: Implications: This is a strategic diversification move: Anupam Rasayan is using Bliss GVS to enter pharmaceutical formulations and move further up the healthcare value chai...
